SPA-RQ
Phase 1Small molecule
SPA-RQ is one of 72 small molecule programs targeting Panic Disorder. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
102 competitors in Post-Traumatic Stress Disorder
#DrugCompanyPhaseTrials
1Depakote
AbbViePhase 3
Maviret
AbbViePhase 3
Inderal
WWyeth-Lederle Vaccines
Phase 3
Depakote
TevaPhase 3
Rexulti
OtsukaPhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Abilify
OtsukaPhase 3
Duloxetine Hydrochloride
Eli LillyPhase 3
Keppra
UCBPhase 2
Niacor
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPA-RQ. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details